Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Aplenc

Showing results (151-160 of 254) with videos related to

Pageof 26
Sort By:
The New England Journal of Medicine|March 27, 2013
Chimeric antigen receptor-modified T cells for acute lymphoid leukemiaStephan A Grupp, Michael Kalos, David Barrett, et al.
Medical Care|March 14, 2012
Establishment of an 11-year cohort of 8733 pediatric patients hospitalized at United States free-standing children's hospitals with de novo acute lymphoblastic leukemia from health care administrative dataBrian T Fisher, Tracey Harris, Kari Torp, et al.
JCO Clinical Cancer Informatics|April 10, 2026
Feasibility of Automated Laboratory Data Ascertainment and Transfer From Hospitals Into Medidata Rave Across Pediatric National Cancer Institute-Supported Cooperative GroupsTamara P Miller, Richard Aplenc, Charles Minard, et al.
Cancer Medicine|December 24, 2017
Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232Amanda M DiNofia, Alix E Seif, Meenakshi Devidas, et al.
Blood Cancer Journal|May 23, 2019
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 TrialRoya Rafiee, Lata Chauhan, Todd A Alonzo, et al.
Haematologica|February 8, 2020
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology GroupRichard Aplenc, Soheil Meshinchi, Lillian Sung, et al.
Pediatric Blood & Cancer|October 19, 2023
Racial and ethnic disparities in acuity of presentation among children with newly diagnosed acute leukemiaLena E Winestone, Kelly D Getz, Yimei Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumorsElizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.
JCO Precision Oncology|September 11, 2020
CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology GroupLata Chauhan, Miyoung Shin, Yi-Cheng Wang, et al.
STAR Protocols|August 30, 2025
Protocol for plasma membrane enrichment by ultracentrifugation for mass spectrometry of cell lines, xenografts, and patient tumorsAmber K Hamilton, Brian Mooney, Tina Glisovic-Aplenc, et al.
Pageof 26

Showing results (151-160 of 254) with videos related to

Sort By:
Pageof 26
The New England Journal of Medicine|March 27, 2013
Chimeric antigen receptor-modified T cells for acute lymphoid leukemiaStephan A Grupp, Michael Kalos, David Barrett, et al.
Medical Care|March 14, 2012
Establishment of an 11-year cohort of 8733 pediatric patients hospitalized at United States free-standing children's hospitals with de novo acute lymphoblastic leukemia from health care administrative dataBrian T Fisher, Tracey Harris, Kari Torp, et al.
JCO Clinical Cancer Informatics|April 10, 2026
Feasibility of Automated Laboratory Data Ascertainment and Transfer From Hospitals Into Medidata Rave Across Pediatric National Cancer Institute-Supported Cooperative GroupsTamara P Miller, Richard Aplenc, Charles Minard, et al.
Cancer Medicine|December 24, 2017
Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232Amanda M DiNofia, Alix E Seif, Meenakshi Devidas, et al.
Blood Cancer Journal|May 23, 2019
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 TrialRoya Rafiee, Lata Chauhan, Todd A Alonzo, et al.
Haematologica|February 8, 2020
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology GroupRichard Aplenc, Soheil Meshinchi, Lillian Sung, et al.
Pediatric Blood & Cancer|October 19, 2023
Racial and ethnic disparities in acuity of presentation among children with newly diagnosed acute leukemiaLena E Winestone, Kelly D Getz, Yimei Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumorsElizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.
JCO Precision Oncology|September 11, 2020
CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology GroupLata Chauhan, Miyoung Shin, Yi-Cheng Wang, et al.
STAR Protocols|August 30, 2025
Protocol for plasma membrane enrichment by ultracentrifugation for mass spectrometry of cell lines, xenografts, and patient tumorsAmber K Hamilton, Brian Mooney, Tina Glisovic-Aplenc, et al.
Pageof 26